|
Avanir's docosanol cream approved for marketing in Israel, Korea, and Canada.
Publication: Virus Weekly Publication Date: 09-JUL-02 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2002 NewsRX
2002 JUL 9 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced that the Ministry of Health in Israel has approved the company's docosanol 10% cream for marketing as a topical treatment for cold sores. Docosanol 10% cream will be marketed in Israel by CTS Chemical Industries under an exclusive license agreement that provides royalties to Avanir on wholesale product sales. CTS expects to begin marketing the product, which it will sell under the trade name "Abrax", in October 2002. The Avanir-developed product received...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Virus Weekly |
Schering-Plough reports on Peg-Intron and Rebetol combination therapy ...
July 09, 2002
|
Clinicians should consider influenza A and B when diagnosing a febrile...
July 09, 2002
|
Study concludes benefits of anti-HIV therapy during pregnancy outweigh...
July 09, 2002
|
Novirio becomes Idenix Pharmaceuticals, Inc.(Brief Article)
July 09, 2002
|
Estrogen may be associated with virus implicated in cervical cancer.
July 09, 2002
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
